Cover Image
市場調查報告書

高血壓治療藥的亞太地區市場 (到2021年):雖然產品平台貧乏,由於高血壓患者的增加使市場成長

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

出版商 GBI Research 商品編碼 336890
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
高血壓治療藥的亞太地區市場 (到2021年):雖然產品平台貧乏,由於高血壓患者的增加使市場成長 Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline
出版日期: 2015年07月01日 內容資訊: 英文 82 Pages
簡介

2014年時,在亞太地區的主要4個國家 (中國、印度、澳洲、日本) ,高血壓的患病者有5億1700萬人,到2011年以1.2%的年複合成長率(CAGR) 持續增加,估計同年達到5億6100萬人。患病者的增加,導致醫療費增加和今後的發病率進一步上升,不過,政治家和一般市民對於這件事的認識很低,沒有充足的對策。

本報告提供亞太地區高血壓的治療藥市場相關分析、疾病概要和到目前為止的臨床實驗的進展、主要的已上市產品的特徵、現在臨床實驗中的開發中產品的概要、亞太地區市場趨勢預測 (今後8年份) 等調查評估。

第1章 目錄

第2章 簡介

  • 病理生理學
  • 病因
  • 前兆、症狀
  • 並存症、併發症
  • 診斷
    • 開業醫生、診所的血壓監測
    • 門診病人窗口的血壓監測
    • 家庭的血壓監測
    • 其他技術
    • 特定組織的損傷的診斷
    • 妊娠中的高血壓的診斷
  • 分類
  • 流行病學
  • 預後
  • 治療、管理
    • 治療策略

第3章 已上市產品

  • 主要的已上市產品
    • Prestalia (perindopril arginine + amlodipine besylate)
    • Azilva (azilsartan medoxomil)
    • Amlodipine besylate
    • Telmisartan
    • Aliskiren
    • Olmesartan medoxomil
    • Valsartan
    • Losartan
    • Exforge (amlodipine + valsartan)
  • 已上市產品的熱圖

第4章 開發中產品

  • 整體開發平台
    • 各分子類型
    • 各作用機制
  • 臨床實驗分析
    • 臨床實驗的失敗率
    • 臨床實驗的規模
    • 臨床實驗期間
  • 有前途的開發平台治療藥
    • SER-100
    • CS-3150

第5章 市場未來預測 (今後8年份)

  • 亞太地區市場
    • 治療模式
    • 市場規模
  • 澳洲
    • 治療模式
    • 年度治療費用
    • 市場規模
  • 印度
  • 中國
  • 日本
  • 市場促進、阻礙因素

第6章 資本交易與策略性的市場重組

  • 授權合約
    • 主要的契約
  • 共同開發契約
    • 主要的契約

第7章 附錄

  • 所有開發中產品:各相 (階段)
    • 藥物研發階段
    • 前臨床階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 市場預測 (今後8年份)
    • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
  • 市場定義
  • 簡稱集
  • 參考資料
  • 分析方法
  • 關於專門資料的有效性
  • 諮詢方式
  • 法律上的免責聲明

圖表一覽

目錄
Product Code: GBIHC363MR

Executive Summary

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control.

The classes of drugs prescribed to treat hypertension are Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Calcium Channel Blockers (CCB), beta-blockers, renin inhibitors, and diuretics. The percentage of patients treated using monotherapy and combination therapy (including fixed-dose combinations) varies from country to country. The most commonly prescribed drugs in the CCB class are amlodipine and lercanidipine, while the leading ARBs are telmisartan, candesartan, olmesartan, irbesartan, losartan, valsartan, azilsartan medoxomil, and eprosartan. Ramipril, imidapril, perindopril, enalapril, lisinopril, benazepril, fosinopril, trandolapril, and quinapril dominate the ACEIs.

Scope

  • Hypertension prevalence is a prominent contributor to market size in the assessed countries. The market is mostly dominated by generics, and there are only a few patented products.
  • Will generics continue to dominate treatment?
  • How do the elderly populations and their associated risk factors affect prevalence?
  • The current anti-hypertensive therapeutics pipeline is weak, comprising 124 molecules in various stages of development, dominated by small molecules.
  • Will the upcoming molecules change the treatment paradigm in the near future?
  • How will the weak pipeline affect the market?
  • Analysis of clinical trials since 2006 identified that anti-hypertensive products have a high rate of attrition.
  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?
  • Over the 2014-2021 forecast period, the APAC anti-hypertensive therapeutics market is expected to increase in value at a CAGR of 3.4% from $15.7 billion to just over $19.9 billion. Growth is projected to vary considerably across the four assessed markets.
  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will branded products' patent expirations pose a significant threat?
  • Will new market entrants over the forecast period lead to substantial changes in annual therapy costs?

Reasons to buy

  • This report will enable you to -
  • Understand the clinical context of hypertension by considering symptoms, etiology, pathophysiology, co-morbidities and complications, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape, and recognize gaps.
  • Appreciate key anti-hypertensive pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in anti-hypertensive clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for the China, India, Australia, and Japan.
  • Discover trends in licensing and co-development deals concerning anti-hypertensive products and identify the major strategic consolidations that have shaped the commercial landscape.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Pathophysiology
  • 2.2. Etiology
  • 2.3. Signs and Symptoms
  • 2.4. Co-morbidities and Complications
  • 2.5. Diagnosis
    • 2.5.1. Office or Clinic Blood Pressure Monitoring
    • 2.5.2. Ambulatory Blood Pressure Monitoring
    • 2.5.3. Home Blood Pressure Monitoring
    • 2.5.4. Miscellaneous Methods
    • 2.5.5. Diagnosis of Target Organ Damage
    • 2.5.6. Diagnosis of Hypertension in Pregnancy
  • 2.6. Classification
  • 2.7. Epidemiology
  • 2.8. Prognosis
  • 2.9. Treatment and Management
    • 2.9.1. Treatment Strategy

3. Marketed Products

  • 3.1. Key Marketed Products
    • 3.1.1. Prestalia (perindopril arginine + amlodipine besylate)
    • 3.1.2. Azilva (azilsartan medoxomil)
    • 3.1.3. Amlodipine besylate
    • 3.1.4. Telmisartan
    • 3.1.5. Aliskiren
    • 3.1.6. Olmesartan medoxomil
    • 3.1.7. Valsartan
    • 3.1.8. Losartan
    • 3.1.9. Exforge (amlodipine + valsartan)
  • 3.2. Heat Map for Marketed Products

4. Anti-hypertensive Market to 2021 - Pipeline Products

  • 4.1. Overall Pipeline
    • 4.1.1. Pipeline Analysis by Molecule Type
    • 4.1.2. Pipeline Analysis by Mechanism of Action
  • 4.2. Clinical Trial Analysis
    • 4.2.1. Failure Rate
    • 4.2.2. Clinical Trial Size
    • 4.2.3. Duration
  • 4.3. Promising Drug Candidates in Pipeline
    • 4.3.1. SER-100
    • 4.3.2. CS-3150

5. Market Forecast to 2021

  • 5.1. Asia-Pacific Market
    • 5.1.1. Treatment Use Patterns
    • 5.1.2. Market Size
  • 5.2. Australia
    • 5.2.1. Treatment Use Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. India
    • 5.3.1. Treatment Use Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. China
    • 5.4.1. Treatment Use Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Use Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Licensing Agreements
    • 6.1.1. Major Licensing Deals
  • 6.2. Co-development Agreements
    • 6.2.1. Major Co-development Agreements

7. Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III
  • 7.2. Market Forecasts to 2021
    • 7.2.1. Asia-Pacific
    • 7.2.2. China
    • 7.2.3. India
    • 7.2.4. Japan
    • 7.2.5. Australia
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Anti-hypertensive Therapeutics, Possible Co-morbidities
  • Table 2: Anti-hypertensive Therapeutics, Proposal for Outcome-Driven Reference Values for Ambulatory Blood Pressure Measurement (mmHg)
  • Table 3: Anti-hypertensive Therapeutics, Blood Pressure Classification in Adults (mmHg)
  • Table 4: Anti-hypertensive Therapeutics, Definitions of Hypertension by Office and Out-of-Office Blood Pressure Levels (mmHg)
  • Table 5: Anti-hypertensive Therapeutics, Prevalence of Hypertension
  • Table 6: Anti-hypertensive Therapeutics, Suggested Medications for Hypertensive Patients with Certain Medical Conditions
  • Table 7: Anti-hypertensive Therapeutics, Lifestyle Measures and Recommendations
  • Table 8: Anti-hypertensive Therapeutics, Compelling and Possible Contra-indications of Anti-hypertensive Drugs
  • Table 9: Anti-hypertensive Therapeutics, Preference of Drug in Specific Condition/Situation of Hypertensive Patients
  • Table 10: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Discovery, 2015
  • Table 11: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Preclinical, 2015
  • Table 12: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase I, 2015
  • Table 13: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase II, 2015
  • Table 14: Anti-hypertensive Therapeutics, Global, All Pipeline Products, Phase III, 2015
  • Table 15: Anti-hypertensive Therapeutics, Asia-Pacific, Market Forecast, 2014-2021
  • Table 16: Anti-hypertensive Therapeutics , China, Market Forecast, 2014-2021
  • Table 17: Anti-hypertensive Therapeutics , India, Market Forecast, 2014-2021
  • Table 18: Anti-hypertensive Therapeutics , Japan, Market Forecast, 2014-2021
  • Table 19: Anti-hypertensive Therapeutics , Australia, Market Forecast, 2014-2021
  • Table 20: Abbreviations

List of Figures

  • Figure 1: Anti-hypertensive Therapeutics, Physiological Mechanism of Renin Angiotensin Aldosterone System
  • Figure 2: Anti-hypertensive Therapeutics, Global, Prevalence Rate (%), 2007-2010
  • Figure 3: Anti-hypertensive Therapeutics, Treatment Algorithm of Hypertension
  • Figure 4: Anti-hypertensive Therapeutics, Influence of Drugs on the Renin Angiotensin Aldosterone System
  • Figure 5: Anti-hypertensive Therapeutics, Treatment Algorithm, 2014
  • Figure 6: Anti-hypertensive Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products, 2015
  • Figure 7: Anti-hypertensive Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2015
  • Figure 8: Anti-hypertensive Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2015
  • Figure 9: Anti-hypertensive Therapeutics, Global, Pipeline by Mechanism of Action, 2015
  • Figure 10: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate (%), 2015
  • Figure 11: Anti-hypertensive Therapeutics, Global, Clinical Trial Size, 2015
  • Figure 12: Anti-hypertensive Therapeutics, Global, Clinical Trial Duration (months), 2015
  • Figure 13: Anti-hypertensive Therapeutics, Asia-Pacific, Treatment Use Patterns, Patients (million), 2014-2021
  • Figure 14: Anti-hypertensive Therapeutics, Asia-Pacific, Market Size ($bn), 2014-2021
  • Figure 15: Anti-hypertensive Therapeutics, Australia, Treatment Use Patterns, Patients (million), 2014-2021
  • Figure 16: Anti-hypertensive Therapeutics, Australia, Annual Cost of Therapy ($), 2014-2021
  • Figure 17: Anti-hypertensive Therapeutics, Australia, Market Size ($bn), 2014-2021
  • Figure 18: Anti-hypertensive Therapeutics, India, Treatment Use Patterns, Patients (million), 2014-2021
  • Figure 19: Anti-hypertensive Therapeutics, India, Annual Cost of Therapy ($), 2014-2021
  • Figure 20: Anti-hypertensive Therapeutics, India, Market Size ($bn), 2014-2021
  • Figure 21: Anti-hypertensive Therapeutics, China, Treatment Use Patterns, Patients (million), 2014-2021
  • Figure 22: Anti-hypertensive Therapeutics, China, Annual Cost of Therapy ($), 2014-2021
  • Figure 23: Anti-hypertensive Therapeutics, China, Market Size ($bn), 2014-2021
  • Figure 24: Anti-hypertensive Therapeutics, Japan, Treatment Use Patterns (million), 2014-2021
  • Figure 25: Anti-hypertensive Therapeutics, Japan, Annual Cost of Therapy ($), 2014-2021
  • Figure 26: Anti-hypertensive Therapeutics, Japan, Market Size ($bn), 2014-2021
  • Figure 27: Anti-hypertensive Therapeutics, Global, Licensing Deals by Region, Phase and Value, 2006- Q1 2015
  • Figure 28: Anti-hypertensive Therapeutics, Global, Licensing Deals by Phase and Mechanism of Action, 2006-Q1 2015
  • Figure 29: Anti-hypertensive Therapeutics, Global, Licensing Deals by Geography, 2006-Q1 2015
  • Figure 30: Anti-hypertensive Therapeutics, Global, Co-development Deals by Region, Value and Phase, 2006- Q1 2015
  • Figure 31: Anti-hypertensive Therapeutics, Global, Co-development Deals by Phase and Mechanism of Action, 2006-Q1 2015
  • Figure 32: Anti-hypertensive Therapeutics, Global, Co-development Deals by Geography, 2006-Q1 2015
  • Figure 33: GBI Research Market Forecasting Model (Example)
Back to Top